PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10351026

Dissecting cost-effectiveness analysis for preventive interventions: a guide for decision makers.

S M Teutsch·J F Murray
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Decision makers usually limit their use of economic evaluations of preventive interventions to the cost-effectiveness ratio. OBJECTIVE: To show decision makers how economic evaluations can be used to understand the cost-effectiveness of different options for altering health intervention strategies. OBSERVATIONS: Cost-effectiveness analysis provides insights into many factors that contribute to the overall benefits, hazards, and costs of interventions. This article reviews how epidemiologic and intervention characteristics, costs, natural history, targeting, and current interventions influence the value of prevention strategies. CONCLUSION: Understanding the factors that contribute to the overall costs and effectiveness of interventions should allow decision makers to better adapt interventions to their needs.

Explore related subjects

Cost of IllnessCost-Benefit AnalysisDecision Making, OrganizationalGuidelines as TopicMass ScreeningPreventive Health ServicesUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S M Teutsch, J F Murray. 1999. Dissecting cost-effectiveness analysis for preventive interventions: a guide for decision makers.. https://pubmed.ncbi.nlm.nih.gov/10351026/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management.

The purpose of this study was to analyse whether the nationwide application of the national Serbian guideline for diabetes mellitus (NSGDM) would save a relevant amount of disability-adjusted life years (DALYs) and/or reduce the medical cost of treating diabetic patients in Serbia, as compared to the present situation. Disability-adjusted life years were calculated for Serbia and the cost-effectiveness was analysed in eight population groups under ideal and present conditions; prevalent and incident cases were each split up for patients with blood glucose that was well controlled and that was uncontrolled. Under ideal conditions, i.e., according to the NSGDM, 8,031 DALYs could be saved with a potential cost reduction at the same time of approximately 19 million Euros. The implementation of the NSGDM in clinical practice bears a great potential to save lives and reduce years lived with lowered quality of life, but in addition it may reduce costs by about a quarter.

Cost of Illness↗
PubMed2007

Economic aspects of diabetic foot care in a multidisciplinary setting: a review.

BACKGROUND: To evaluate the economic aspects of diabetic foot care in a multidisciplinary setting. METHOD: A review of the English language literature, published from 1966 to November 2005. RESULTS: The results of available studies on the cost-of-illness of diabetic foot problems are difficult to compare. Nevertheless trends concerning excess of costs, protraction in time of costs, positive correlation to severity of ulcer and/or peripheral vascular disease, contribution of in-hospital stay and length of stay, and the patient's own contribution to total costs, are obvious. Only a few cost-effectiveness and cost-utility studies are available. Most use a Markov based model to predict outcome and show an acceptable result on long-term. CONCLUSIONS: Diabetic foot problems are frequent and are associated with high costs. A multidisciplinary approach to diabetic foot problems has proved to be cost saving with regard to cost of treatment itself. Nevertheless, it remained unclear if these savings could offset the overall costs involved in implementing this kind of approach. The few studies that address this issue specifically all show an acceptable cost-effectiveness, but often the profit will be evident after some years only, because long-term costs are involved. Based on these data, policymakers should foresee sufficient reimbursement for preventive and early curative measures, and not only for 'salvage manoeuvres'.

Cost of Illness↗